EXEL•benzinga•
The FDA Has Notified Exelixis That The Supplemental New Drug Application For Cabometyx (Cabozantinib) For Previously Treated Advanced Pancreatic Neuroendocrine Tumors And Advanced Extra-pancreatic Patients Will No Longer Be The Subject Of Discussion At An
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 9, 2025 by benzinga